The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ — Diadem srl , a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that it has been selected as a finalist for both the Gaetano Marzotto Company Prize and the Gaetano Marzotto 2030 Social Impact Special Prize. . MILAN , Nov.

Disease 40

Disease Treatment Production Clinical Trials 40

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. The lengthy process adversely impacts clinical trial start-up time and trial costs.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. trillion per space by 2030.

Disease 52

Disease FDA Therapies Trials 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

APRIL 24, 2021

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). The grant will support African trials of a combination comprising KAF156 and lumefantrine in a new once-daily formulation.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

NOVEMBER 1, 2020

The trial is expected to enroll 160 patients. billion by 2030 2. I am very delighted to learn the swift IND clearance by the US FDA, and we are initiating the phase II clinical trial immediately,” said Dr. Jasmine Cui, the co-founder, chairman, and Chief Executive Officer of InnoCare. About InnoCare Pharma.

Clinical Trials 40

Clinical Trials Trials FDA Treatment 40

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. Adaptive trials allow researchers to modify specific parameters (e.g.,

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

FEBRUARY 24, 2022

– Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for heart failure, regardless of ejection fraction. with more than 8 million cases expected by 2030. . with more than 8 million cases expected by 2030.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  Gepotidacin has shown promising results in clinical trials for uncomplicated urinary tract infections and gonorrhea, demonstrating its potential to address the growing threat of MDR Gram-negative infections.  million deaths associated with it.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

The Pharma Data

MARCH 13, 2021

“Tau has become increasingly validated as a predictive biomarker for Alzheimer’s disease progression, as shown again in this trial,” said Liana G. Patients with treatment discontinuations were allowed to continue in the trial. Apostolova, M.D., In the donanemab arm, 30.5 trailblazer2study.com. Source link:[link].

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

JULY 29, 2021

Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

The Pharma Data

MARCH 9, 2021

Additional data highlight Lilly’s AD program focused on developing both disease-modifying therapies that slow clinical progression by targeting the underlying causes of AD and novel diagnostics and biomarkers to enable a timely and more accurate diagnosis. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. Strong pipeline with robust late-stage development program and broad potential across indications.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. One example is the acquisition of Asklepios BioPharmaceutical (AskBio), a leading company in the field of gene therapy.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

MAY 3, 2021

This includes making COVID-19 therapies available in low- and middle-income countries, as well as hurricane preparedness in the U.S. Lilly ‘s commitment also supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030.

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. by the time Bancel made it over to Flagship, where Afeyan delivered his pitch: He wanted Bancel to work on a startup that had so far hired only a single staff scientist and conducted just one mouse trial. “It was about 6 p.m.

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

APRIL 27, 2021

At the end of the first quarter, Dupixent ® was launched in 49 countries with approximately 260 000 patients on therapy. . reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe. Neurology and Immunology. Net sales (€ million). Change at CER. Lemtrada ®.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

NOVEMBER 5, 2020

REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.”

Production 40

Production Trials FDA FDA Approval 40

The Pharma Data

FEBRUARY 8, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. In 2020, Dupixent ® sales reached €3,534 million, up 73.9% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. In 2020, Dupixent ® sales reached €3,534 million, up 73.9% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Therapies 52

PPD

JANUARY 21, 2025

This decrease brings into sharp focus the growing challenges facing the field: Clinical trials now demand greater complexity, as well as increased data and diversity requirements. Trend 1: Scenario modeling will allow companies to evaluate entire trial timelines, revealing potential bottlenecks that help them achieve optimal outcomes.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

Codon

FEBRUARY 23, 2025

After decades of research into therapies and preventive measures, though, global AIDS deaths have now fallen to about 600,000 annually. Because of PEPFAR’s effectiveness, the United Nations (UN) set an ambitious goal in 2022 to end HIV transmission and eliminate AIDS-related deaths by 2030. million by 2004.

Clinical Trials 70

Clinical Trials Virus Vaccine DNA 70